Targeting Major
Cancer Markets
Edison Oncology is a biomarker-driven, small molecule, targeted oncology company that was founded in 2018 by experienced life science veterans to develop and commercialize new therapies targeting the fight against cancer.
Identifying and Advancing Underdeveloped Drug Candidates
By leveraging our deep understanding of tumor biology and expertise in translational drug development, we aim to identify and acquire promising, underdeveloped drug candidates and strategically advance them for patients whose tumors are most likely to respond.
Developing Disruptive Drug Candidates
We are advancing a pipeline of novel small-molecule therapies, each offering multiple “shots on goal” across both orphan and broader oncology markets. Our mission is to address significant unmet medical needs and improve outcomes for cancer patients whose tumors carry mutations that our product candidates are specifically designed to target.
Our Approach to Improve Cancer Patient Outcomes
Cancer arises from genetic mutations that disrupt normal cellular function, enabling tumors to grow, spread, and resist treatment. At Edison Oncology, we strive to improve patient outcomes by applying our deep expertise in tumor biology and cancer pharmacology to identify, acquire, and advance promising yet underdeveloped drug candidates.
Business Development Opportunities
Please contact us if you are interested in business opportunities.
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.
No posts were found for provided query parameters.